ABCB1 and non-small cell lung carcinoma: For example, the ABCB1 (MDR1) inhibitors tariquidar and CBT-1(R) [175–177] were tested unsuccessfully in two phase III clinical studies where treatment of stage IIIB/IV NSCLC patients with tariquidar in combination with vinorelbine or carboplatin/paclitaxel did not show any advantages and the trial was finished prematurely (ID NCT00042302 and NCT00042315) [178].